



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

February 23, 2021

Via E-mail

Mr. Paul Stone
Senior Vice President and Chief Financial Officer
IDEAYA Biosciences, Inc.
7000 Shoreline Court, Suite 350
South San Francisco, CA 94080

Re: IDEAYA Biosciences, Inc.
Form 10-Q for the quarterly period ended September 30, 2020
Exhibit 10.1 Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement
Filed November 12, 2020
File No. 001-38915

Dear Mr. Stone:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance